Asian Journal of Biomedical and Pharmaceutical Sciences

Reach Us +1 (202) 780-3397

Perspective - Asian Journal of Biomedical and Pharmaceutical Sciences (2024) Volume 14, Issue 107

Advances in clinical pharmacology and molecular drug design: A new era in hospital pharmacy.

Lu Chen *

Department of Pharmacology, Chengdu University of Traditional Chinese Medicine, Chengdu, China

*Corresponding Author:
Lu Chen
Department of Pharmacology, Chengdu University of Traditional Chinese Medicine, Chengdu, China
E-mail: Lu@Chen.12.cn

Received: 02-Sep-2024, Manuscript No. AABPS-24-151586; Editor assigned: 03-Sep-2024, PreQC No. AABPS-24-151586 (PQ); Reviewed: 16-Sep-2024, QC No. AABPS-24-151586; Revised: 20-Sep-2024, Manuscript No. AABPS-24-151586(R); Published: 27-Sep-2024, DOI: 10.35841/aabps-14.107.258

Citation: : Chen L. Advances in clinical pharmacology and molecular drug design: A new era in hospital pharmacy. Asian J Biomed Pharm Sci. 2024;14(107):258

Introduction  

Clinical pharmacology and molecular drug design are transforming hospital pharmacy by tailoring treatments to specific patient needs and advancing precision medicine. With the rise of complex diseases and antibiotic resistance, there is a growing demand for targeted therapies that maximize efficacy and minimize adverse effects. This article explores the impact of clinical pharmacology and the innovation of molecular drug design in improving patient care in hospital settings. Clinical pharmacology is essential in hospital pharmacy, helping pharmacists make informed decisions about drug administration and monitoring. By studying drug interactions, pharmacokinetics, and pharmacodynamics, clinical pharmacology ensures that patients receive the optimal therapeutic regimen. It also assists in preventing drug toxicity, especially in vulnerable populations like the elderly and patients with multi-drug regimens [1, 2].

Molecular drug design is an innovative approach that allows researchers to create drugs based on the molecular structure of disease-causing agents. This precision-focused technique is particularly beneficial for complex diseases like cancer, where conventional drugs may fall short. Using computational tools and bioinformatics, researchers can design molecules that precisely target specific pathways, offering a promising avenue for creating highly effective, less toxic medications [3, 4].

Moreover, biomedical research has been instrumental in the development of treatments for a wide range of conditions, including cancer, cardiovascular diseases, and neurological disorders. Scientists in this field work on everything from drug discovery and personalized medicine to gene therapy and regenerative medicine. These breakthroughs are transforming the way we approach previously incurable diseases. For example, advances in immunotherapy have revolutionized cancer treatment, offering hope to patients who had few options before. One of the most pressing issues in hospital pharmacy is antibiotic resistance, which threatens the efficacy of standard treatments for bacterial infections. Clinical pharmacology, combined with molecular drug design, can contribute to the development of new antibiotics those target resistant strains. By designing molecules that bypass bacterial defense mechanisms, hospitals can better address infections that are currently difficult to treat [5, 6].

The combination of clinical pharmacology and molecular drug design is pivotal for advancing personalized medicine, which tailors treatments to individual genetic profiles. Personalized medicine in hospitals has led to more accurate dosing, reduced adverse drug reactions, and improved patient outcomes. Molecular drug design supports this by enabling the customization of drug compounds to match the genetic markers of individual patients, providing them with the most effective treatment [7, 8].

While the integration of clinical pharmacology and molecular drug design holds great promise, there are challenges, including high costs and the need for advanced technological infrastructure. Future developments aim to address these hurdles, with the potential for artificial intelligence to streamline the drug design process and make personalized therapies more accessible [9, 10].

Conclusion  

Clinical pharmacology and molecular drug design are ushering in a new era for hospital pharmacy, marked by precise, effective treatments that enhance patient safety. Through innovations in molecular drug design and the application of pharmacological knowledge, hospitals are better equipped to address complex diseases and antibiotic resistance. As technology and research continue to advance, these fields will play an increasingly vital role in shaping the future of healthcare.

References

  1. Lu CYNew technology for detecting multidrug-resistant pathogens in the clinical microbiology laboratory. Emerg Infect Dis. 2001;306–311.

    2. Google Scholar, Cross Ref

  2. Dong X. Weighted locality collaborative representation based on sparse subspace . J Visual Com Image Repr . 2019;58:187–94.

    3. Indexed at, Google Scholar, Cross Ref

  3. Huang DC. A computer assisted method for leukocyte nucleus segmentation and recognition in blood smear images.. J Systems Soft . 2012;85(9):2104–18.

    4. Google Scholar, Cross Ref

  4. Yang-Mao SF. Edge enhancement nucleus and cytoplast contour detector of cervical smear images.. Cybernetics. 2008;38(2):353–66.

    5. Indexed at, Google Scholar, Cross Ref

  5. Salem NM. Segmentation of white blood cells from microscopic images using K-means clustering.. NRSC. 2014.371–76.

    6. Google Scholar, Cross Ref

  6. Ali ZSurgical Apgar score in prediction of post-operative complications in gynecological surgery Int J Reprod Contraception, Obstet Gynecol. 2016;5:1796–1800.

    7. Google Scholar, Cross Ref

  7. Orberger M. Association between the surgical Apgar score and perioperative complications after radical prostatectomy . Urol Int. 2017;98:61–70.

    8. Indexed at, Google Scholar, Cross Ref

  8. Kinoshita M. New surgical scoring system to predict postoperative mortality.. J Anesth. 2017;31:198–205.

    9. Google Scholar, Cross Ref

  9. Glass NEThe surgical Apgar score predicts postoperative icu admission.. J Gastrointest Surg. 2015;19(3):445–50.

    10. Indexed at, Google Scholar, Cross Ref

  10. Prince ACUtility of the surgical Apgar score in head and neck squamous cell carcinoma . Otolaryngol Neck Surg. 2018;159(3):466–72.

    11. Indexed at, Google Scholar, Cross Ref

Get the App